In an era of targeted therapy, acute myeloid leukemia (AML) treatment selection is centered around assessing both a patient’s fitness and genetic profile. In this first podcast, join our AML expert for a didactic discussion with a hematopathologist on the role of cytogenetic and molecular testing on AML treatment decisions. Don’t miss the opportunity to hear experts deliver evidence-based strategies on utilizing both patient and disease factors to determine when to wait to initiate AML treatment until receipt of genetic testing results and with which agents.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/podcast/role-cytogenetic-molecular-testing-aml-prognostication-treatment-decisions
- Start Date: 2024-12-20 06:00:00
- End Date: 2024-12-20 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: Rigel Pharmaceuticals, Inc. - Amount: 16666.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest